16:27 EST UroGen Pharma (URGN) files automatic mixed securities shelf
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN:
- Urogen Pharma’s Promising Growth and Demand Surge Support Buy Rating
- UroGen Pharma reports Q3 EPS (69c), consensus (68c)
- UroGen Pharma announces preliminary results from Phase 3 UTOPIA trial
- UroGen Pharma’s UGN-104 Study: A Potential Game-Changer in Urothelial Cancer Treatment
- UroGen Pharma’s Phase 3 Study on UGN-103: A Potential Game-Changer in Bladder Cancer Treatment